Quantitative morphologic assessment of immunoreactivity in regional lymph nodes of patients with carcinoma of the breast - PubMed (original) (raw)
. 1975 Jun;140(6):919-24.
- PMID: 1129683
Quantitative morphologic assessment of immunoreactivity in regional lymph nodes of patients with carcinoma of the breast
M Wernicke. Surg Gynecol Obstet. 1975 Jun.
Abstract
The main quantitative problem in the pathologic evaluation of carcinoma of the breast is how to appraise host resistance. To study this in 107 patients with radically excised carcinoma of the breast, the axillary lymph nodes were weighed, the average sinus histiocytosis was estimated, and the plasma cells in the medullary cords were counted and expressed as a plasma cell index. The product of the lymphoid weight, the average sinus histiocytosis and the plasma cell index multiplied by 0.1 is called the hyperplasia index, which expresses quantitatively the cell mediated immunity and the humoral immunity in the axillary lymph nodes. The hyperplasia index was correlated with the metastatic tumor weight in the primary tumor with blood vessel invasion, lymphoid infiltration and volume of the tumor. There was a significant inverse relationship, p smaller than 0.001, between the hyperplasia index and the ratio of metastatic tumor weight to lymphoid weight. A significant direct relationship was found in the women with blood vessel invasion and low hyperplasia index values with increased metastatic tumor weight ratio to lymphoid weight, p smaller than 0.01. In patients without metastatic lymph nodes, there was a direct relationship between high hyperplasia indexes and lymphoid infiltration of the frank tumor, p smaller than 0.05. The hyperplasia index is considered a quantitative morphologic evaluation of the regional host defense reaction in the axillary lymph nodes, reflecting the antigenic strength of the tumor and the immune response to it.
Similar articles
- [Cellular reactions in tumor stroma and reactive changes in regional lymph nodes in breast cancer].
Fedin IuV, Ermilova VD. Fedin IuV, et al. Vopr Onkol. 1984;30(11):38-44. Vopr Onkol. 1984. PMID: 6334934 Russian. - Distribution of mast cells in the axillary lymph nodes of breast cancer patients.
Naik R, Baliga P, Bansal R, Pai M. Naik R, et al. J Indian Med Assoc. 1997 Dec;95(12):606-7. J Indian Med Assoc. 1997. PMID: 9586403 - [Management of the axilla in breast cancer: evidences and unresolved issues].
Fodor J, Polgár C, Péley G, Németh G. Fodor J, et al. Orv Hetil. 2001 Sep 9;142(36):1941-50. Orv Hetil. 2001. PMID: 11680099 Review. Hungarian. - Correlation of tumor size and axillary lymph node involvement with prognosis in patients with T1 breast carcinoma.
Abner AL, Collins L, Peiro G, Recht A, Come S, Shulman LN, Silver B, Nixon A, Harris JR, Schnitt SJ, Connolly JL. Abner AL, et al. Cancer. 1998 Dec 15;83(12):2502-8. Cancer. 1998. PMID: 9874455 Review.
Cited by
- Leukocytes in mammary development and cancer.
Coussens LM, Pollard JW. Coussens LM, et al. Cold Spring Harb Perspect Biol. 2011 Mar 1;3(3):a003285. doi: 10.1101/cshperspect.a003285. Cold Spring Harb Perspect Biol. 2011. PMID: 21123394 Free PMC article. Review. - Inflammation and breast cancer. Balancing immune response: crosstalk between adaptive and innate immune cells during breast cancer progression.
DeNardo DG, Coussens LM. DeNardo DG, et al. Breast Cancer Res. 2007;9(4):212. doi: 10.1186/bcr1746. Breast Cancer Res. 2007. PMID: 17705880 Free PMC article. Review. - Naturally occurring B-cell responses to breast cancer.
Coronella-Wood JA, Hersh EM. Coronella-Wood JA, et al. Cancer Immunol Immunother. 2003 Dec;52(12):715-38. doi: 10.1007/s00262-003-0409-4. Epub 2003 Aug 15. Cancer Immunol Immunother. 2003. PMID: 12920480 Free PMC article. Review.